Stratec Se

Stratec Se Liabilities

The The Liabilities of Stratec Se (SBS.DE) as of Oct 23, 2026 is 206.06 M EUR. In the previous year, The Liabilities was 202.53 M EUR — a change of 1.75% (higher).

Liabilities

206.06 MEUR

YoY

1.75%

Last updated:

In 2025, Stratec Se's total liabilities amounted to 206.06 M EUR, a 1.75% difference from the 202.53 M EUR total liabilities in the previous year.

The Stratec Se Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Liabilities
Date
Liabilities
Jan 1, 2018
123.08 M EUR
Jan 1, 2019
140.41 M EUR
Jan 1, 2020
159.36 M EUR
Jan 1, 2021
162.77 M EUR
Jan 1, 2022
172.32 M EUR
Jan 1, 2023
233.25 M EUR
Jan 1, 2024
202.53 M EUR
Jan 1, 2025
206.06 M EUR
The Stratec Se Liabilities history
YEARLiabilitiesYoY
206.06 MEUR+1.75%
202.53 MEUR-13.17%
233.25 MEUR+35.36%
172.32 MEUR+5.87%
162.77 MEUR+2.14%
159.36 MEUR+13.50%
140.41 MEUR+14.08%
123.08 MEUR+16.18%
105.94 MEUR-7.27%
114.25 MEUR+298.65%
28.66 MEUR+11.53%
25.70 MEUR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Stratec Se Stock analysis

What does Stratec Se do? The company Stratec SE is a German company operating in the medical technology industry. It was founded in 1984 and has since become a leading provider of automation solutions and diagnostic instruments. Stratec's business model is based on the development and production of devices and systems used in medical diagnostics. The company focuses in particular on the areas of immunology, clinical chemistry, and hematology. Stratec also offers innovative solutions in microscopy and cell analysis. In the "automation solutions" division, Stratec develops systems for the automation of laboratory processes. These are mainly used in clinical diagnostics to accelerate and simplify workflow. Examples include sample identification systems, pipetting robots, and analysis devices. In the "in vitro diagnostics" division, Stratec offers products for determining blood values. This includes devices for determining glucose, cholesterol, and hemoglobin levels, as well as devices for infection diagnostics and tumor and allergy diagnostics. Another division of Stratec is "microscopy." The company manufactures automated microscope systems, primarily used in biomedical research to analyze cells and tissues. In the "cell analysis" division, Stratec offers innovative methods for analyzing cells, such as cell growth and vitality determination. Stratec always focuses on tailoring the design of its products to the needs of its customers. High flexibility in device development and manufacturing is therefore an important factor in the company's success. In addition to device development and production, Stratec also provides services related to its products. These include installation, maintenance, and on-site repair of devices for customers. Stratec SE operates internationally and has branches in Europe, Asia, and America. The company employs over 1,000 people worldwide. Overall, Stratec SE is a successful and renowned provider of medical devices and systems for automating laboratory processes. With its diverse product portfolio and high flexibility in customer support, Stratec has earned a leading position in the industry. Stratec Se is one of the most popular companies on Eulerpool.

Liabilities Details

Assessing Stratec Se's Liabilities

Stratec Se's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Stratec Se's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Stratec Se's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Stratec Se's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Stratec Se’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Stratec Se stock

The Liabilities of Stratec Se is 206.06 M EUR in 2025.

The Liabilities of Stratec Se changed from 202.53 M EUR to 206.06 M EUR, representing a 1.75% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The Liabilities Stratec Se since 2006 – with annual values, charts, and detailed analysis.

The Liabilities's EUR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Liabilities's Stratec Se historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Balance Sheet — Stratec Se

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — Stratec Se